Skip to main content

MDxHealth S.A. (MDXH) Stock Forecast

Data as of Aug 7, 2026

Healthcare · Current price $0.47 (+7.53%)

Consensus Target
$4.00
Upside
+847.8%
Analysts
3
Rating
Buy(2.00)

Price Target Range

Low $4.00High $4.00

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy3
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

No analyst price targets available.

MDXH vs Sector & Market

MetricMDXHHealthcare AvgLarge Cap Avg
Analyst Rating2.002.252.42
Analyst Count3818
Target Upside+847.8%+16315.1%+17.2%
P/E Ratio-3.043.4135.26

Revenue Estimates

PeriodLowAvgHigh#
2026-09-30$35M$36M$36M1
2026-12-31$36M$36M$37M2
2027-03-31$36M$36M$37M1
2027-06-30$39M$40M$41M2
2027-09-30$42M$42M$43M2
2027-12-31$44M$44M$45M1
2028-12-31$193M$195M$196M1
2029-12-31$230M$232M$234M2

EPS Estimates

PeriodLowAvgHigh#
2026-09-30$-0.09$-0.09$-0.091
2026-12-31$-0.10$-0.10$-0.091
2027-03-31$-0.10$-0.10$-0.091
2027-06-30$-0.04$-0.04$-0.041
2027-09-30$-0.03$-0.03$-0.031
2027-12-31$-0.03$-0.03$-0.031
2028-12-31$0.07$0.07$0.071
2029-12-31$0.35$0.35$0.351

Frequently Asked Questions

What is the analyst consensus for MDXH?

The consensus among 3 analysts covering MDxHealth S.A. (MDXH) is Buy with an average price target of $4.00.

What is the highest price target for MDXH?

The highest analyst price target for MDXH is $4.00.

What is the lowest price target for MDXH?

The lowest analyst price target for MDXH is $4.00.

How many analysts cover MDXH?

3 analysts have issued ratings for MDxHealth S.A. in the past 12 months.

Is MDXH a buy or sell right now?

Based on 3 analyst ratings, MDXH has a consensus rating of Buy (2.00/5) with a +847.8% upside to the consensus target of $4.00.

What are the earnings estimates for MDXH?

Analysts estimate MDXH will report EPS of $-0.09 for the period ending 2026-09-30, with revenue estimated at $36M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.